Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $1.83 which represents a decrease of $-0.09 or -4.69% from the prior close of $1.92. The stock opened at $1.97 and touched a low of ...

Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has received an average recommendation of “Hold” from the ten ratings ...

On Monday, Fate Therapeutics Inc (FATE) stock saw a modest uptick, ending the day at $2.72 which represents a slight increase of $0.07 or 2.64% from the prior close of $2.65. The stock opened at $ and ...

Thrivent Financial for Lutherans increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 24.7% in the third quarter, according to the company in its most recent ...

About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell ...

About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential ...

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...